Helixmith

Seoul, KR

Hybrid — also manufactures internal programs

Plasmid AAV

Program data pending ClinicalTrials.gov matching · Last scored 2026-04-02

59.0

Signal Score

○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (2) ○ EMA GMP ○ MHRA GMP

Quick Facts: Helixmith

Signal Score: 59.0/100 (as of 2026-04-02)
Quality Compliance: Assessment pending
Headquarters: Seoul, KR
Modalities: Plasmid, AAV
Active Programs: No ClinicalTrials.gov matches confirmed
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

No FDA inspection records found for this manufacturer

Quality score requires FDA inspection data

Operations —

No ClinicalTrials.gov facility matches confirmed for this manufacturer.

Programs — no verified data

Sponsors— no verified data

ModalitiesPlasmid, AAV

No clinical trial matches found for this manufacturer

Operational score requires ClinicalTrials.gov data

Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Private company

Financial assessment: 60.0/100

Capacity

1 manufacturing site

Recent Press2 articles

1 manufacturing site: Seoul, KR

Modalities: Plasmid, AAV

Capacity assessment: 58.0/100

Recent News 2 articles

general 2026-03-20

Amyotrophic Lateral Sclerosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharmaceuticals - Barchart

Source →

general 2026-03-20

Source →

Represent this organization? Contact us to verify or update this profile.

See all CDMOs in:

Plasmid CDMOs → AAV CDMOs →